LakeShore Biopharma Co., Ltd.
DelistedCIK 1946399fmd_0HMSTJQ8TZADDJZNRPA94T5NJGManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Apr 01, 2020 to Mar 31, 2025, 5 periods
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Total revenues | 257 | 503 | 687 | 573 | 615 |
| Cost of revenue | 60 | 117 | 153 | 118 | 108 |
| Net interest income | (30) | (3) | (31) | (44) | (16) |
| Gross profit | 197 | 386 | 534 | 456 | 507 |
| Research and development | 94 | 211 | 319 | 303 | 146 |
| Selling, general and administrative | – | 284 | 346 | 441 | 410 |
| Total operating expenses | 323 | 505 | 673 | 902 | 593 |
| Operating income | (126) | (119) | (139) | (446) | (86) |
| Interest expense | 6 | 3 | 32 | 48 | 17 |
| Other non-operating income (expense) | (49) | 18 | (5) | (9) | (15) |
| Income before taxes | (174) | (101) | (144) | (455) | (101) |
| Income tax expense | 17 | 5 | 1 | (22) | (1) |
| Net income from continuing operations | (192) | (106) | (145) | (433) | (100) |
| Net income | (192) | (106) | (145) | (433) | (100) |
| Net income to common shareholders | (208) | (237) | (283) | (433) | (100) |